Want to share news to millions of readers?

Lupin receives USFDA nod for rufinamide tablets to treat seizures

Business Standard LogoBusiness Standard1 mo ago

Lupin receives USFDA nod for rufinamide tablets to treat seizures - Business Standard

Quick Summary:

The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of rufinamide tablets of strengths 100 mg, 200 mg, and 400 mg, Lupin said in a statement.

Pharmaceuticals firm Lupin Ltd on Thursday said it has received approval from the US health regulator to market its generic rufinamide tablets used in the treatment seizures.

These are the generic equivalent of banzel tablets of same strengths of Eisai Inc, it added.

More Pictures


Article Details

Author / Journalist: Press Trust of India

Category: EconomyFinance

Topics: Approval Usfda Rufinamide Firm Pharmaceuticals Drug Seizures Lupin Generic Tablets Treat

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2022-08-18, 15:41:00

News Timezone: GMT +5:00

News Source URL:

Language: English

Reading Time: 2 minutes read

Article Length: 201 words

Coverage Area: India

Availability: Desktop Web, Mobile Web

News ID: 147860

View Article Analysis

About Business Standard

Business Standard Logo

Main Topics: EconomyFinance

Official Website:

Update Frequency: 224 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 6h ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

News Language: English

RSS Feed: Available (XML)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

BEAMSTART brings you the latest news, jobs, and events from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting events, and discover incredible career opportunities with the world's most innovative companies.

© Copyright 2022 BEAMSTART. All Rights Reserved.